Poikiloderma of Civatte
Poikiloderma of Civatte
Are You Confident of the Diagnosis?
Characteristic findings on physical examination
Poikiloderma of Civatte is a combination of linear telangiectasia, reticulate hyperpigmentation and slight atrophy occurring most commonly in sun-exposed areas, including the sides of the neck, lower anterior neck, and “V” of the chest (
Poikiloderma of Civatte on the neck.
Expected results of diagnostic studies
Diagnosis is made clinically. However, histology shows hyperkeratosis, epiderma l atrophy with basal cell liquefactive degeneration, pigmentary incontinence, telangiectasisa, variable superficial dermal lymphohistiocytic infiltrate, and marked solar elastosis
Differential diagnosis includes Riehl’s melanosis and erythromelanosis follicularis faciei et colli. Riehl’s melanosis tends to demonstrate less reticular spotted brown pigmentation with absent or minimal telangiectasia. The face is characteristically involved (forehead and temples most common). Erythromelanosis follicularis faciei et colli, which is more common in young males, showed brownish-red hyperpigmentation, telangiectasia and minute follicular papules involving the face and neck.
Other conditions in the differential diagnosis include poikiloderma of connective tissue disease and chronic graft versus host disease. These conditions can be ruled out on the basis of the patient’s history.
Who is at Risk for Developing this Disease?
Poikiloderma of Civatte usually affects men and women in the fourth and fifth decade of life. Fair-skinned individuals are at an increased risk, especially those with a history of significant sun exposure. Postmenopausal females are more commonly affected.
What is the Cause of the Disease?
The exact etiology and pathogenesis are unknown. Exposure to ultraviolet radiation is thought to be the main cause. Other implicated factors include genetic predisposition, menopause, and phototoxic or photoallergic reactions to ingredients in fragrances and cosmetics.
Systemic Implications and Complications
No systemic involvement or complications are seen with poikiloderma of Civatte.
Treatment is limited and focuses primarily on laser therapy (
Treatment options for poikiloderma of Civatte Medical options
|Intense pulsed light (IPL)|
|Pulse dye laser (PDL)|
|Potassium titanyl phosphate (KTP) laser|
Optimal Therapeutic Approach for this Disease
Medical treatment for this condition is limited. Photoprotection with chemical and physical sunscreens may limit progression. Topical tretinoin, adapalene, and tazoretne can be used to limit the effects of photoaging. However, they only provide limited improvement in dyspigmentation observed with this condition and results are anecdotal. All three retinoids at all concentrations have shown anecdotal benefit.
Determination of which retinoid to use will be based on insurance coverage and tolerability. Tazarotene tends to cause the most irritation and adapalene causing the least. When using a retinoid to treat poikiloderma of Civatte, it would be best to start with a lower strength to ensure better tolerability and adherence.
Physical modalities are the main treatment option. However, it is difficult to achive complete clearance with these modalities as well. Unfortunately data is mostly anecdotal. Intense pulsed light (IPL) can target both the telangiectasias and hyperpigmentation. Various studies with IPL have reported clearance rates of up to 75% with 5% incidence of side effects including posttreatment erythema, swelling, mild purpura, and appearance of untreated stripes. One study reported three treatments sessions at 3-week intervals, although this may vary.
Fractional photothermolysis particularly improves the dyspigmentation while also targeting the vascular and textural components of poikiloderma of Civatte. One study used ablative fractional photothermolysis for one to three treatment sessions at 6-8 week intervals with significant improvement. Pulsed dye laser (PDL) has been used to primarily target the vascular component of these lesions. However, treatment is limited by purpura, mottled appearance, and scarring.
Patients should be advised to use broad-spectrum sunscreens and photoprotective clothing to minimize progression. Prior to laser treatment, patients should be advised that results are variable and complete clearance may not be achieved. Side effects of the particular laser being used should be reviewed. The importance of photoprotection posttreatment should be emphasized.
Unusual Clinical Scenarios to Consider in Patient Management
Altough poikiloderma of Civatte occurs in otherwise healthy patients, similar poikilodermatous changes can be associated with rare genodermatoses, including Rothmund-Thomson syndrome, Kindler syndrome, Cockayne syndrome, and dyskeratosis congenita. Additionally, if poikiloderma is observed in non-photodistributed areas, mycosis fungoides should also be considered in the differential diagnosis.
What is the Evidence?
Tierney, E, Hanke, C. "Treatment of poikiloderma of Civattte with ablative fractional laser resurfacing:prospective study and review of the literature". J Drugs Dermatol. vol. 8. 2009. pp. 527-34.(Prospective pilot study of 10 patients treated with an ablative fractioinated carbon dioxide laser (10,600 nm) for a series of 1 to 3 treatment session adminstered at 6- to 8-week intervals. The number of treatment sessions was determined by the degree of clinical improvement. Blinded physician photograph analysis was performed at 2 months postttreatment, which showed improvement in erythema/telangiectasia, dyschromia, skin texture, laxity, and overall cosmetic outcome.)
Rusciani, A, Motta, A, Fino, P, Menichini, G. "Treatment of poikiloderma of Civatte using intense pulsed light source: 7 years of experience". Dermatol Surg. vol. 34. 2008. pp. 314-9.(Retrospective review of 175 patients treated at one center with intense pulsed light. Patients received three treatment sessions each session at 3-week intervals and were evaluated 3 months after the last treatment session. More than 80% of the vascular and pigmented components of poikiloderma of Civatte was observed with minimal side effects).
James, WD, Berger, TG, Elston, DM. "Andrews' Diseases of the Skin". Clinical Dermatology. Saunders Elsevier. 2006. pp. 30-1.(Section in chapter that discuss actinic injury and possible treatments for improving photodamage.)
Behroozan, D, Goldberg, L, Glaich, A, Dai, T, Friedman, P. "Fractional photothermolysis for treatment of poikiloderma of Civatte". Dermatol Surg. vol. 32. 2006. pp. 298-301.(Case report of one patient with poikiloderma of Civatte on the neck treated with a single treatment of 1,550nm Fraxel, SR laser. Significant improvement in degree of erythema, dyschromia and texture was noted 2 weeks after treatment by both patient and physician. Improvement was persistant at 2 months posttreatment.)
Katoulis, A, Stavrineas, N, Georgala, S, Bozi, E, Kalogeromitros, D, Koumantaki, E. "Poikiloderma of Civatte:a clinical and epidemiological study". J Eur Acad Dermatol Venereol. vol. 19. 2005. pp. 444-8.(Observational study conducted in Greece of 50 patients, describing the clinical presentations and epidemiological characteristics of poikiloderma of Civatte.)
McKee, PH, Calonje, E, Granter, SR. "Pathology of the skin with clinical correlations". vol. 245. Mosby Elsevier. 2005.(Section in book chapter discussing the histological features of poikiloderma of Civatte.)
Katoulis, A, Stavrineas, N, Katsarou, A, Antoniou, C, Georgala, S, Rigopoulos, D. "Evaluation of the role of contact sensitization and photosensitivity in the pathogenesis of poikiloderma of Civatte". Br J Dermatol. vol. 147. 2002. pp. 493-7.(Greek study of 32 patients with poikiloderma of Civatte who underwent patch testing with the European standard series and fragrance series and photopatch testing. Statistically significant difference was observed between the frequency of positive reaction to fragrances between the poikiloderma of Civatte group and the control group, comprised of 97 patients, who were patch tested for suspected allergic contact dermatitis. This raises the possibility of contact sensitization playing a pathogenetic role in the development of poikiloderma of Civatte.)
Katoulis, A, Stavrineas, N, Georgala, S, Katsarou-Katsari, A, Koumantaki-Mathioudaki, E, Antoniou, C. "Familial cases of poikiloderma of Civatte: genetic implications in its pathogenesis". Clin Exp Dermatol. vol. 24. 1999. pp. 385-7.(Report of seven cases of poikiloderma of Civatte occurring among members of two Greek families, raising the possibility that genetic predisposition may lead to the development of this condition.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma